Unknown

Dataset Information

0

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.


ABSTRACT: Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with potential therapeutic applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of Nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.

SUBMITTER: Valenzuela Nieto G 

PROVIDER: S-EPMC7870875 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8546686 | biostudies-literature
| S-EPMC7830243 | biostudies-literature
| S-EPMC8863326 | biostudies-literature
| S-EPMC1924550 | biostudies-literature
| S-EPMC7591918 | biostudies-literature
| S-EPMC3990716 | biostudies-literature
| S-EPMC7301900 | biostudies-literature
| S-EPMC7307151 | biostudies-literature
| S-EPMC9580340 | biostudies-literature
| S-EPMC10294592 | biostudies-literature